Appendix 1—table 6. Summary of all the association tests for GRS.

All GRS related tests from the main text. The notation of MED12mut + and MED12mut- refer to the numbers of MED12-mutation-positive and -negative tumors, respectively. The tests include Wilcoxon rank-sum and models for linear and negative binomial (NB) regression (variable ~GRS). The P values were adjusted for FWER with the Holm-Bonferroni method (Q). Significant associations (Q < 0.05) are shown bolded. Note that population association tests include only the female controls.

GRS *	Cohort	Variable	Test	N cases	N controls	Rate ratio	P	Q
Stage 1	Helsinki	UL phenotype	Rank-sum (one-tailed)	457	8899	-	8.3e-10	1.1e-08
Stage 2	NFBC	UL phenotype	Rank-sum (one-tailed)	459	2351	-	1.1e-05	1.1e-04
Stage 2	Helsinki	Total number of ULs	NB	457	-	1.25	0.00105	0.0032
Stage 2	Helsinki	Age at hysterectomy	Linear	392	-	0.50	0.48	0.48
Stage 2	Helsinki	Number of MED12mut+	NB	457	-	1.43	3.2e-04	0.002
Stage 2	Helsinki	Number of MED12mut-	NB	457	-	0.79	0.0266	0.053
Stage 2	Helsinki	One-or-more MED12mut+	Rank-sum	334	123	-	5.3e-04	0.0026
Stage 2	Helsinki	All MED12mut+	Rank-sum	221	123	-	7.9e-04	0.0032
Stage 2	African #	UL phenotype	Rank-sum (one-tailed)	296	1256	-	1.3e-05	1.2e-04
Stage 2	Caribbean#	UL phenotype	Rank-sum (one-tailed)	668	2041	-	6.7e-05	5.4e-04
Stage 2	Irish #	UL phenotype	Rank-sum (one-tailed)	398	6208	-	8.3e-06	9.1e-05
Stage 2	Indian #	UL phenotype	Rank-sum (one-tailed)	203	2567	-	2.9e-04	0.0020
Stage 2	Other white #	UL phenotype	Rank-sum (one-tailed)	647	8982	-	6.9e-09	8.3e-08

^*Based either on stage 1 (UKBB GWAS) or stage 2 (meta-analysis of UKBB and Helsinki).

^# An independent subset of UKBB data (stratified based on self-reported UKBB annotation).